Abstract Library
Members may log into MY ENETS to visit the abstract library from previous ENETS conferences.
Participants of the ENETS Conference in 2024 can now access the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more via My ENETS.
ENETS Abstract Search
Introduction: Bronchial Carcinoids (BCs) are rare neuroendocrine neoplasms arising from respiratory epithelium. The only effective treatment option is surgery, but its efficacy is frequently limited by metastatic spread. Everolimus prolongs progression free survival but patients may develop resistance. Previous studies demonstrated that Everolimus reduces viability of NCI-H720 cells (Atypical Carcinoid) but not of NCI-H727 cells (Typical Carcinoid). Everolimus decreases Ciclyn D1 protein levels in both cell lines but NCI-H727 cells survive, indicating a derangement in cell cycle control.
Conference: 15th Annual ENETSConcerence (2018)
Presenting Author:
Authors: Bresciani G, Riva E, Ambrosio M, Zatelli M,
Keywords: bronchial carcinoids, cell cycle, cyclins, cdks, target therapy, everolimus, dinaciclib, palbociclib,
Introduction: mTOR inhibitors (mTORi) such as RAD001 demonstrated promising anti-cancer effect in NETs. Autophagy, a cell survival mechanism, is activated by mTORi. We have recently shown in the human NET cell line BON1 that autophagy is essential for cell survival. Treatment with CQ alone or together with mTORi robustly inhibited cell proliferation and survival, suggesting that treatment with CQ may potentiate the anti-tumorigenic effects of mTORi.
Conference: 14th Annual ENETSConcerence (2017)
Presenting Author: Avniel-Polak S
Authors: Avniel-Polak S, Leibowitz G, Gross D, Grozinsky-Glasberg S,
Introduction: The therapy options for patients with advanced NETs are limited. The mTOR inhibitors (mTORi), Torin1 and NVP-BEZ235, are known to suppress cell proliferation in NETs. However, cancer cells may use mTORi-induced autophagy to prolong survival, evading the anti-cancer effect. Chloroquine (CQ) and hydroxychloroquine (HCQ) have been shown to inhibit autophagy.
Conference: 12th Annual ENETSConcerence (2015)
Presenting Author: Avniel- Polak S
Authors: Avniel-Polak S, Leibowitz G, Glaser B, Gross D, Grozinsky-Glasberg S,
Introduction: Platin-etoposide (PE), the gold standard regimen for poorly differentiated neuroendocrine carcinomas, might be effective in well-differentiated pancreatic neuroendocrine tumors (WD-PNETs) with a high Ki-67 proliferation index.
Conference: 11th Annual ENETSConcerence (2014)
Presenting Author: BAUDIN E
Authors: Roquin G, Baudin E, Lombard-Bohas C, Cadiot G, Dominguez S,
Keywords: platin/etoposide, pNETs, Ki-67,
Introduction: Most patients with neuroendocrine tumors (NETs) require systemic treatment, often with a limited therapeutic effect. RAD001 and Torin1 are mTOR inhibitors (mTORi) known to suppress cell proliferation in NETs. However, cancer cells may use mTORi-induced autophagy to escape the anti-proliferative effect and to prolong cell survival. Chloroquine (CQ) and hydroxychloroquine (HCQ) inhibit autophagy.
Conference: 11th Annual ENETSConcerence (2014)
Presenting Author: Glasberg S
Authors: Avniel-Polak S, Leibowitz G, Glaser B, Gross D, Glasberg S,
Keywords: NETs, autophagy, mTOR inhibitors,